Cenicriviroc Mesylate

Cenicriviroc Mesylate

• CAS Number: 497223-28-6
• UNSPSC Description: Cenicriviroc Mesylate (TAK-652 Mesylate) is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.
• Target Antigen: CCR; HIV
• Type: Reference compound
• Related Pathways: Anti-infection;GPCR/G Protein;Immunology/Inflammation
• Applications: COVID-19-anti-virus
• Field of Research: Infection; Inflammation/Immunology; Endocrinology
• Assay Protocol: https://www.medchemexpress.com/Cenicriviroc_Mesylate.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(/C1=C/C2=CC(C3=CC=C(OCCOCCCC)C=C3)=CC=C2N(CC(C)C)CCC1)NC4=CC=C([S@](CC5=CN=CN5CCC)=O)C=C4.OS(=O)(C)=O
• Molecular Weight: 793.05
• References & Citations: [1]Lefebvre E, et al. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016 Jun 27;11(6):e0158156.|[2]Visseaux B, et al. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates. PLoS One. 2015 Aug 6;10(8):e0134904.|[3]Lalezari J, et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):118-25.|[4]Baba M, et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother. 2005 Nov;49(11):4584-91.
• Shipping Conditions: Room Temperature
• Clinical Information: Phase 3